Darovasertib, a novel treatment for metastatic uveal melanoma

• Principais autores: Lei Cao (Autor), Shuzhen Chen (Autor), Rainie Sun (Autor), Charles R. Ashby (Autor), Liuya Wei (Autor), Zoufang Huang (Autor), Zhe-Sheng Chen (Autor)
• Formato: Livro
• Publicado em: Frontiers Media S.A., 2023-07-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

The FDA granted orphan drug designation to darovasertib, a first-in-class oral, small molecular inhibitor of protein kinase C (PKC), for the treatment of uveal melanoma, on 2 May 2022. Primary uveal melanoma has a high risk of progressing to metastatic uveal melanoma, with a poor prognosis. The acti...